TNF and psoriatic arthritis: Agents such as infliximab, adalimumab, and etanercept are widely used to manage inflammatory diseases by blocking TNF-α activity.30 These inhibitors have demonstrated efficacy in controlling symptoms and preventing disease progression in conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and inflammatory bowel disease.16